Rifapentine (2 brand names, 1 dosage form, 1 route)
Available dosage forms: TABLET.
Routes of administration: ORAL.
Brand Names
- PRIFTIN
- RIFAPENTINE
Adverse Reactions
The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling: •Hepatotoxicity [see Warnings and Precautions (5.1)] •Hypersensitivity [see Contraindications (4.1) and Warnings and Precautions (5.2)] •Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.3)] •Paradoxical Drug Reactions [see Warnings and Precautions (5.5)] •Discoloration of Body Fluids [see Warnings and Precautions (5.7)] •Clostridioides Difficile–Associated Diarrhea [see Warnings and Precautions (5.8)] •Porphyria [see Warnings and Precautions (5.9)]
Mechanism of Action
Rifapentine, a cyclopentyl rifamycin, is an antimycobacterial agent [see Microbiology (12.4)].
Overdosage
While there is no experience with the treatment of acute overdose with rifapentine tablets, clinical experience with rifamycins suggests that gastric lavage to evacuate gastric contents (within a few hours of overdose), followed by instillation of an activated charcoal slurry into the stomach, may help adsorb any remaining drug from the gastrointestinal tract. Rifapentine and 25-desacetyl rifapentine are 97.7% and 93.2% plasma protein bound, respectively. Rifapentine and related compounds excreted in urine account for only 17% of the administered dose, therefore, neither hemodialysis nor forced diuresis is expected to enhance the systemic elimination of unchanged rifapentine from the body of a patient with rifapentine tablets overdose.